NeuroPace (NPCE) Q4 2025 earnings review
Shedding DIXI to Become a High-Margin Pure Play
NeuroPace finished 2025 with strong 24% revenue growth in Q4, driven by a 26% surge in core RNS System sales. Management reached a critical strategic milestone by early-terminating its distribution agreement for lower-margin DIXI Medical products on December 31. This transforms NeuroPace into a pure-play neuromodulation company. While this move makes 2026 total revenue guidance ($98-$100M) look optically flat compared to 2025 ($100M), it masks an accelerating underlying RNS growth rate of 20-22% and will push gross margins structurally above 81%. However, eliminating DIXI's cash contribution will push the company back into negative Adjusted EBITDA territory for 2026.
🐂 Bull Case
Stripping out the ~50% margin DIXI business instantly elevates the company's gross margin profile. 2026 Non-GAAP gross margin is guided to 81.5%-82.5%, firmly placing NeuroPace in top-tier medtech profitability territory.
CMS finalized aggressive rate hikes for 2026: +43% for initial implant procedures and +47% for replacements. This removes financial friction for hospitals and significantly incentivizes adoption.
🐻 Bear Case
NeuroPace celebrated a positive $0.9M Adjusted EBITDA in Q4. But without DIXI's $5.9M annual operating income contribution, continuing operations are deeply unprofitable, leading to a -$9.5M EBITDA guidance midpoint for 2026.
After announcing a delay in the pediatric indication submission during the Q3 call (originally expected H2 2025), the Q4 release offered no updates on this critical growth pillar.
⚖️ Verdict: 🟢
Bullish. The optical stall in 2026 total revenue is a strategic necessity. Ridding the company of the low-margin DIXI distribution business clarifies the investment thesis: NeuroPace is a rapidly growing, >80% gross margin pure-play with major regulatory catalysts (IGE) approaching in mid-2026.
Key Themes
The DIXI Profitability Illusion
Management touted a second consecutive quarter of positive Adjusted EBITDA ($0.9M in Q4). However, this narrative is contradicted by the continuing operations data. DIXI generated $1.5M in operating income in Q4. Stripping that out, the core RNS business posted an Adjusted EBITDA loss of $0.6M. With DIXI officially discontinued, the cash cushion is gone, explaining why 2026 guidance calls for EBITDA to reverse back to an annual loss of $9M to $10M.
Massive Medicare Rate Increases
A major macro and regulatory tailwind has materialized: CMS finalized highly favorable rates for CY2026. The Outpatient Prospective Payment System (OPPS) rule increases hospital Medicare reimbursement for RNS replacements by 47%. Concurrently, the Physician Fee Schedule (PFS) boosts doctor pay by 43% for initial implants and 45% for replacements. This dramatically improves the unit economics for healthcare providers and is expected to be a primary catalyst for accelerating utilization.
IGE Indication Moving Toward the Finish Line
The company officially submitted its PMA-Supplement to the FDA to expand the RNS System indication to Idiopathic Generalized Epilepsy (IGE). Backed by NAUTILUS trial data showing a robust 77% median seizure reduction, management expects approval by mid-2026. Because IGE patients do not require invasive phase two monitoring, this approval could significantly shorten the patient care pathway and speed up adoption.
Evolution into an AI-Driven Data Platform
NeuroPace submitted 'Seizure ID' to the FDA for review. This represents the first of a planned suite of 'NeuroPace AI' tools. By leveraging years of proprietary, patient-level brain data, Seizure ID aims to automate and accelerate iEEG review for clinicians. While initially a support tool rather than a direct revenue generator, it deepens the company's competitive moat against traditional VNS and DBS therapies by making data analysis significantly easier for physicians.
Operating Expense Step-Up to Support Growth
To support the 20-22% core RNS growth and prepare for the IGE launch, spending is accelerating. 2026 Non-GAAP operating expenses are guided to $90-$92M. For comparison, 2025 Non-GAAP operating expenses for continuing operations (excluding DIXI) were $81.2M. This implies an 11-13% YoY increase in the core cost base, meaning operating leverage will take a slight pause in 2026.
Project CARE Expanding the Funnel
The strategy to push RNS treatment beyond Level 4 Comprehensive Epilepsy Centers and into Level 3/community settings is yielding results. Management noted all-time highs in prescribers, accounts, and patient pipeline in Q4, directly validating the community outreach and Direct-to-Consumer (DTC) marketing investments.
Other KPIs
Accelerating. Total gross margin in Q4 was 77.4%, but the underlying RNS gross margin reached 81.9% for the full year (up 350 basis points YoY). Favorable pricing, positive product mix, and manufacturing efficiencies are driving this metric higher, proving the scalability of the core hardware business.
Stable. Up slightly from $60.0M in Q3 2025. With long-term debt at $58.9M, the balance sheet remains adequately capitalized to fund operations through to cash flow breakeven, despite the expected EBITDA drag in 2026 from the DIXI exit.
Guidance
Accelerating on an underlying basis. While optically flat vs $100M in FY25, the FY25 continuing operations baseline (excluding DIXI) was roughly $84.4M. The guidance implies 16-18% growth on the continuing business, driven by a 20-22% projected increase in core RNS revenue.
Stable. Down sequentially from Q4's $26.6M reported total, but entirely explained by the removal of ~$3.3M in Q4 DIXI sales and typical Q1 seasonality. The midpoint ($21.5M) represents a clean, RNS-only baseline.
Accelerating. A massive structural step-up from 77.2% in FY25. This is the direct, mathematical result of terminating the lower-margin (~50%) DIXI distribution agreement and relying purely on the 80%+ margin RNS system.
Reversing. Down from a reported loss of ($5.0) million in FY25. Because DIXI generated $5.9 million in operating income in FY25, removing it causes total company profitability to dip in the near term while commercial investments for the IGE launch ramp up.
Key Questions
Bridging the Post-DIXI EBITDA Gap
With DIXI's $5.9M operating income removed and operating expenses scaling to $90M+, how should investors model the timeline to reach sustainable cash flow breakeven based purely on the core RNS business?
Pediatric Indication Update
The Q3 call noted a delay in the pediatric indication submission due to FDA and NEST protocol alignment. There was no update in the Q4 release. Is this still an active near-term catalyst, and what is the revised timeline?
Impact of 2026 Reimbursement Increases
CMS granted >40% payment increases for CY2026. Have you historically seen immediate volume acceleration following such substantial reimbursement bumps, or is there a lag in hospital purchasing behavior?
Seizure ID Commercial Strategy
Seizure ID was submitted to the FDA as a clinical support tool. Will the NeuroPace AI suite remain a free value-add to drive hardware adoption, or is there a longer-term plan to monetize it as a SaaS offering?